Global Sglt2 Inhibitors Market Size & Outlook, 2023-2030
Global sglt2 inhibitors market, 2018-2030 (US$M)
Related Markets
Global sglt2 inhibitors market highlights
- The global sglt2 inhibitors market generated a revenue of USD 15,852.3 million in 2023 and is expected to reach USD 29,427.0 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 9.2% by 2030.
- In terms of segment, jardiance (empagliflozin) accounted for a revenue of USD 8,338.9 million in 2023.
- Inpefa (sotagliflozin) is the most lucrative drug segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 15,852.3 million |
| Market revenue in 2030 | USD 29,427.0 million |
| Growth rate | 9.2% (CAGR from 2023 to 2030) |
| Largest segment | Jardiance (empagliflozin) |
| Fastest growing segment | Inpefa (sotagliflozin) |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Inpefa (sotagliflozin) , Qtern (dapagliflozin/saxagliptin), Other SGLT2 Inhibitors |
Other key industry trends
- In terms of revenue, the North America accounted for 40.9% of the global sglt2 inhibitors market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, South Africa is the fastest growing regional market and is projected to reach USD 313.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
SGLT2 Inhibitors Market Scope
SGLT2 Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global sglt2 inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sglt2 inhibitors market will help companies and investors design strategic landscapes.
Jardiance (empagliflozin) was the largest segment with a revenue share of 52.6% in 2023. Horizon Databook has segmented the Global sglt2 inhibitors market based on jardiance (empagliflozin), farxiga (dapagliflozin), invokana (canagliflozin), inpefa (sotagliflozin) , qtern (dapagliflozin/saxagliptin), other sglt2 inhibitors covering the revenue growth of each sub-segment from 2018 to 2030.
- Global SGLT2 Inhibitors Drug Outlook (Revenue, USD Million, 2018-2030)
- Jardiance (empagliflozin)
- Farxiga (dapagliflozin)
- Invokana (canagliflozin)
- Inpefa (sotagliflozin)
- Qtern (dapagliflozin/saxagliptin)
- Other SGLT2 Inhibitors
- Global SGLT2 Inhibitors Indication Outlook (Revenue, USD Million, 2018-2030)
- Type 2 Diabetes
- Cardiovascular Diseases
- Chronic Kidney Disease (CKD)
- Other Indications
- Global SGLT2 Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Reasons to subscribe to Global sglt2 inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global sglt2 inhibitors market databook
-
Our clientele includes a mix of sglt2 inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global sglt2 inhibitors market , including forecasts for subscribers. This global databook contains high-level insights into Global sglt2 inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global sglt2 inhibitors market size, by regions, 2018-2030 (US$M)
Top 10 countries: Sglt2 inhibitors market size, 2023 (US$M)
Global sglt2 inhibitors market share, by drug, 2023 & 2030 (%, US$M)
Sglt2 inhibitors market: Opportunity assessment by country
Global sglt2 inhibitors market, by region, 2023 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
